 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | Erleada (apalutamide) / J&J, Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer (clinicaltrials.gov) - Jul 14, 2022
P2, N=900, Recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not yet recruiting --> Recruiting | Initiation date: Jul 2022 --> Feb 2020 | Trial primary completion date: Dec 2029 --> Dec 2026
- | Erleada (apalutamide) / J&J, Airui'en (rezvilutamide) / Jiangsu Hengrui Pharma
New P2 trial, Metastases: Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer (clinicaltrials.gov) - Jun 7, 2022
P2, N=900, Not yet recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- ||| Lynparza (olaparib) / Merck (MSD), AstraZeneca
P3 data, Journal, HEOR, BRCA Biomarker, PARP Biomarker: Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. (Pubmed Central) - Apr 5, 2022
P3
Olaparib was associated with reduced pain burden and better-preserved HRQOL compared with the two control drugs in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations who had disease progression after a previous next-generation hormonal drug. Our findings support the clinical benefit of improved radiographical progression-free survival and overall survival identified in PROfound.
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
Trial completion: Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients (clinicaltrials.gov) - Nov 10, 2013
P1, N=27, Completed, Sponsor: Astellas Pharma Europe BV
Our findings support the clinical benefit of improved radiographical progression-free survival and overall survival identified in PROfound. Active, not recruiting --> Completed
- | Xtandi (enzalutamide capsule) / Pfizer, Astellas
New P1 trial: Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients (clinicaltrials.gov) - Jul 16, 2013
P1, N=27, Completed, Sponsor: Astellas Pharma Europe BV